Pfizer Ltd.

Pfizer has reached a new 52-week low, continuing a downward trend with a notable decline over the past four days. The stock is trading below all key moving averages and has underperformed compared to the broader market, reflecting ongoing challenges within the pharmaceuticals sector.

Pfizer has reported its financial results for the quarter ending December 2024, revealing significant challenges. While the company achieved its highest cash and cash equivalents in recent periods, key performance indicators such as profit before tax, profit after tax, and net sales have all declined, indicating operational difficulties.

Pfizer's stock has faced a significant decline, falling for five consecutive days and accumulating a total drop of 10.12%. The company is currently trading below multiple moving averages, reflecting ongoing challenges. Over the past month, its stock has decreased by 8.47%, underperforming compared to the broader market.

Pfizer's shares have declined for four consecutive days, resulting in a total drop of 7.74%. The stock is trading below key moving averages and has underperformed the broader pharmaceuticals sector. Over the past month, Pfizer's stock fell by 6.05%, contrasting with a 4.11% drop in the Sensex.

Pfizer has recently experienced a change in evaluation, reflecting its current market conditions and financial performance. The company reported modest year-over-year growth in net sales and operating profit for Q2 FY24-25, alongside notable metrics in cash flow and investor participation, indicating ongoing financial dynamics.

Pfizer Ltd. experienced a decline on January 22, 2025, closing at Rs 4791, while the Sensex posted a modest gain. Despite a slight increase over the past month, Pfizer's stock is trading below its moving averages, indicating challenges within the pharmaceuticals sector.

Pfizer Ltd. has been added to MarketsMOJO's list following a recent adjustment in its evaluation. The stock demonstrated a positive performance, gaining 3.54% on January 7, 2025, and showing resilience against sector trends. Key moving averages indicate a mixed short-term outlook, highlighting ongoing market dynamics.

Pfizer Ltd. has undergone a revision in its score following a recent decline in stock performance. The stock underperformed its sector and experienced a notable downturn after a brief period of gains. Additionally, it has been added to MarketsMOJO's list, reflecting ongoing market interest amid fluctuating conditions.

Pfizer Ltd. has been added to MarketsMOJO's list following a recent adjustment in its evaluation. The stock demonstrated a strong performance, gaining for three consecutive days and significantly outperforming its sector. Despite some volatility, Pfizer's stock price remains above several key moving averages, indicating a positive trend in its market position.

Pfizer has recently undergone a revision in its score by MarketsMOJO, reflecting changes in its financial metrics and market position. The company demonstrates strong management efficiency and a solid balance sheet, although it faces challenges with long-term growth and valuation concerns. Pfizer has also been added to MarketsMOJO's list, indicating increased interest from institutional investors.

Pfizer Ltd. has been added to MarketsMOJO's list following a revision in its score, reflecting recent market dynamics. Despite a notable increase in stock price, Pfizer continues to trade below key moving averages, indicating ongoing challenges. The stock's performance remains cautious amid broader market trends.

Pfizer has experienced a revision in its score by MarketsMOJO, reflecting concerns over its long-term growth trajectory. Despite a recent return and profit increase, key performance indicators have shown weakness, prompting an adjustment in evaluation. The stock has also been added to MarketsMOJO's list, highlighting ongoing market scrutiny.

Pfizer Ltd. has experienced a revision in its stock evaluation following a recent decline in performance. The stock's score has been adjusted amid consecutive losses, reflecting its underperformance against the broader market. Additionally, Pfizer has been added to MarketsMOJO's list, indicating a shift in market sentiment.

Pfizer has experienced a notable adjustment in its evaluation, reflecting recent market challenges. The stock's performance has been impacted by a downward trend, leading to its addition to MarketsMOJO's list. Despite these fluctuations, Pfizer maintains its position as a significant player in the pharmaceutical sector.

Pfizer ., a leading pharmaceutical company, experienced a -3.03% decline in its stock on November 13, 2024. This underperformance was reflected in the stock's current trend, with a 'Hold' recommendation from MarketsMOJO. The stock has also underperformed the overall market in the past month.

On November 12, 2024, Pfizer ., a leading pharmaceutical company, saw a 3.23% increase in its stock, outperforming the sector by 2.2%. This follows two days of falling prices and an intraday high of Rs 5345. Despite trading below some moving averages, the stock has shown strong 1-day and 1-month performance compared to the market.

Pfizer, a leading pharmaceutical company, has reported its Q2 FY24-25 financial results. While the company's performance has remained flat, there are positive trends in PAT, Net Sales, and PBT. However, concerns arise from declining Operating Cash Flow, Debtors Turnover Ratio, and DPS. MarketsMOJO advises holding positions in Pfizer's stock.

Pfizer, a leading pharmaceutical company, saw a 3.1% increase in its stock on October 17, 2024. This rise is attributed to the company's strong performance in the market, with its stock outperforming the sector by 3.28%. Pfizer's stock is currently rated as 'Hold' by MarketsMOJO, and is trading higher than its moving averages, indicating a positive trend and potential for growth.

Pfizer ., a top pharmaceutical company, has seen a 3.46% increase in its stock on October 15, 2024, outperforming the sector by 3.18%. This marks the second consecutive day of gains, with a total increase of 4.18% in the past two days. The stock is currently trading higher than its moving averages, showcasing a strong upward trend. Despite market fluctuations, Pfizer .'s stock has consistently outperformed the Sensex, demonstrating its resilience and stability. Financial analysis platform MarketsMOJO has given a 'Hold' recommendation for the stock, based on its current performance and market conditions.